Harvey Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-24,765
| Closed | -$1.56M | – | 76 |
|
|
2020
Q3 | $1.56M | Sell |
24,765
-1,800
| -7% | -$125K | 0.7% | 42 |
|
|
2020
Q2 | $2.04M | Sell |
26,565
-35,825
| -57% | -$2.75M | 1.01% | 33 |
|
|
2020
Q1 | $4.66M | Sell |
62,390
-25,400
| -29% | -$1.76M | 3.15% | 12 |
|
|
2019
Q4 | $5.7M | Sell |
87,790
-1,425
| -2% | -$92.8K | 2.53% | 11 |
|
|
2019
Q3 | $5.65M | Sell |
89,215
-600
| -0.7% | -$39.2K | 2.81% | 10 |
|
|
2019
Q2 | $6.07M | Sell |
89,815
-850
| -0.9% | -$55.9K | 2.92% | 9 |
|
|
2019
Q1 | $5.89M | Sell |
90,665
-1,680
| -2% | -$112K | 2.83% | 10 |
|
|
2018
Q4 | $5.78M | Sell |
92,345
-2,750
| -3% | -$192K | 3.07% | 7 |
|
|
2018
Q3 | $7.34M | Buy |
95,095
+600
| +0.6% | +$45.3K | 2.92% | 10 |
|
|
2018
Q2 | $6.69M | Sell |
94,495
-1,325
| -1% | -$93.6K | 2.66% | 11 |
|
|
2018
Q1 | $7.22M | Sell |
95,820
-280
| -0.3% | -$22.3K | 2.7% | 11 |
|
|
2017
Q4 | $6.88M | Sell |
96,100
-7,110
| -7% | -$540K | 2.49% | 15 |
|
|
2017
Q3 | $8.36M | Sell |
103,210
-13,050
| -11% | -$998K | 3.37% | 9 |
|
|
2017
Q2 | $8.23M | Buy |
116,260
+300
| +0.3% | +$20K | 3.53% | 7 |
|
|
2017
Q1 | $7.88M | Sell |
115,960
-2,580
| -2% | -$181K | 3.54% | 9 |
|
|
2016
Q4 | $8.49M | Sell |
118,540
-4,825
| -4% | -$359K | 3.95% | 5 |
|
|
2016
Q3 | $9.76M | Sell |
123,365
-300
| -0.2% | -$24.4K | 3.01% | 5 |
|
|
2016
Q2 | $10.3M | Buy |
123,665
+2,600
| +2% | +$231K | 5.17% | 3 |
|
|
2016
Q1 | $11.1M | Sell |
121,065
-4,375
| -3% | -$395K | 5.39% | 3 |
|
|
2015
Q4 | $12.7M | Sell |
125,440
-1,200
| -0.9% | -$125K | 5.01% | 3 |
|
|
2015
Q3 | $12.4M | Buy |
126,640
+5,690
| +5% | +$632K | 4.96% | 3 |
|
|
2015
Q2 | $13.9M | Sell |
120,950
-12,950
| -10% | -$1.42M | 4.71% | 5 |
|
|
2015
Q1 | $13.1M | Sell |
133,900
-16,975
| -11% | -$1.72M | 4.83% | 4 |
|
|
2014
Q4 | $14.2M | Buy |
150,875
+50
| +0% | +$5.17K | 5.45% | 5 |
|
|
2014
Q3 | $16.1M | Sell |
150,825
-17,975
| -11% | -$1.76M | 6.3% | 2 |
|
|
2014
Q2 | $14M | Buy |
168,800
+525
| +0.3% | +$40.9K | 5.01% | 4 |
|
|
2014
Q1 | $11.9M | Buy |
168,275
+7,130
| +4% | +$559K | 4.75% | 6 |
|
|
2013
Q4 | $12.1M | Buy |
161,145
+14,750
| +10% | +$1.03M | 5% | 5 |
|
|
2013
Q3 | $9.2M | Sell |
146,395
-20,875
| -12% | -$1.25M | 4.67% | 6 |
|
|
2013
Q2 | $8.57M | Buy |
+167,270
| New | +$8.72M | 5.32% | 4 |
|
Other funds holding GILD
Harvey Capital Management's GILD Position: Q4 2020 in Review
Harvey Capital Management sold out of Gilead Sciences (GILD) in Q4 2020, closing a stake of 24,765 shares — an estimated $1.56M sold.
Harvey Capital Management first reported a position in GILD in Q2 2013 and held it in 30 quarters. The position peaked at $16.1M in Q3 2014. 1,563 funds tracked by Wall St. Rank hold GILD as of Q4 2020.
- Harvey Capital Management reported no remaining Gilead Sciences position as of Q4 2020 after selling out during the quarter.
- Harvey Capital Management sold 24,765 Gilead Sciences shares in Q4 2020, an estimated $1.56M.
- Harvey Capital Management first reported a position in Gilead Sciences in Q2 2013 and held it in 30 quarters.
- Harvey Capital Management's Gilead Sciences position peaked at $16.1M in Q3 2014.
- 1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2020.
Based on Harvey Capital Management's 13F filing for Q4 2020, filed 10 Feb 2021.